


Q1 What is your age?


Answered: 40 Skipped: 0



ANSWER CHOICES	RESPONSES
Under 18 years old	2.50% 1
18-25 years old	50.00% 20
26-35 years old	40.00% 16
36-45 years old	7.50% 3
46-55 years old	0.00% 0
56 years old and above	0.00% 0
TOTAL	40

Q2 Are you studying in or previously studied in a field related to biology/pharmacy/medicine?


Answered: 40 Skipped: 0



ANSWER CHOICES	RESPONSES	
Yes	35.00%	14
No	65.00%	26
TOTAL		40

Q3 Are you familiar with the common treatment methods for obesity-related knee osteoarthritis, such as weight reduction therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), joint-protective medications, and surgical treatment?


Answered: 39 Skipped: 1



ANSWER CHOICES	RESPONSES	
Yes	25.64%	10
No	74.36%	29
TOTAL		39

Q4 Do you believe that compared to traditional treatments for obesity-related knee osteoarthritis like weight reduction therapy, anti-inflammatory treatment, and surgical treatment, miRNA-based biological therapy has fewer side effects?


Answered: 40 Skipped: 0



ANSWER CHOICES	RESPONSES
Yes	20.00% 8
No	7.50% 3
Not sure	72.50% 29
TOTAL	40

Q5 What do you think is the biggest challenge in the development and use of biological treatments for obesity-related knee osteoarthritis?


Answered: 40 Skipped: 0



ANSWER CHOICES	RESPONSES	
Cost	30.00%	12
Accessibility of treatment	32.50%	13
Lack of knowledge among medical professionals	25.00%	10
Side effects	12.50%	5
Other	0.00%	0
TOTAL		40

Q6 In our project, we use miRNA inhibitors to target and suppress highly expressed miRNAs in adipose tissue exosomes of obese osteoarthritis patients. These inhibitors are locally injected, aiming to achieve both weight reduction and joint protection. What concerns do you have about our new therapy?

Answered: 40 Skipped: 0



ANSWER CHOICES	RESPONSES	
No concerns	2.50%	1
Safety (whether this therapy might have toxic side effects on the body)	70.00%	28
Effectiveness (the therapy's impact on treating obesity-related joint osteoarthritis)	62.50%	25
Cost-effectiveness (the expenses associated with this therapy)	47.50%	19
Other	0.00%	0
Total Respondents: 40		

Q7 The development of miRNA-based drugs requires three phases of testing: cell, animal, and clinical trials. Drugs that pass all three phases can be approved for market release. If both traditional methods and the new therapy were available after clinical trials, which one would you prefer?

Answered: 31 Skipped: 9

ANSWER CHOICES	RESPONSES	
Traditional therapy, because :	48.39%	15
New therapy, because :	54.84%	17

Q8 If you have more opinions or suggestions for our project, please write below.

Answered: 11 Skipped: 29